• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content

Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this presentation? Why not share!

Introduction

on

  • 751 views

 

Statistics

Views

Total Views
751
Views on SlideShare
751
Embed Views
0

Actions

Likes
0
Downloads
4
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • Basic research is a strength of the CCR, with areas of investigation including: immunology, carcinogenesis, human genetics, mouse genetics, viral oncology, HIV, chromatin biology, structural biology, DNA replication and recombination, signal transduction, apoptosis, cell cycle regulation, cytokines and chemokines, cellular, molecular and developmental biology, medicinal chemistry and natural products chemistry, molecular pharmacology, xenobiotic metabolism, radiation biology, computational biology and bioinformatics. Areas of excellence in clinical and translational research include: cancer vaccines, clinical proteomics, molecular targets of cancer, molecular imaging, biologic mediators, cell-based therapies, immunotoxin therapy, radiation therapy, cancer genetics, molecular epidemiology, cancer prevention, multidrug resistance, clinical pharmacology, angiogenesis and molecular pathology. Programs encompass investigators, organized within a specific field of research, who are working together to solve a complex scientific problem. AIDS Vaccine Program – Larry Arthur, Ph.D Computational Applications Program – Stan Burt, Ph.D HIV Drug Resistance Program – John Coffin, Ph.D. Molecular Targets Drug Discovery Program Mouse Cancer Genetics Program – Neal Copeland, Ph.D. Radiation Oncology Sciences Program (ROSP) – C. Norman Coleman, M.D.
  • Basic research is a strength of the CCR, with areas of investigation including: immunology, carcinogenesis, human genetics, mouse genetics, viral oncology, HIV, chromatin biology, structural biology, DNA replication and recombination, signal transduction, apoptosis, cell cycle regulation, cytokines and chemokines, cellular, molecular and developmental biology, medicinal chemistry and natural products chemistry, molecular pharmacology, xenobiotic metabolism, radiation biology, computational biology and bioinformatics. Areas of excellence in clinical and translational research include: cancer vaccines, clinical proteomics, molecular targets of cancer, molecular imaging, biologic mediators, cell-based therapies, immunotoxin therapy, radiation therapy, cancer genetics, molecular epidemiology, cancer prevention, multidrug resistance, clinical pharmacology, angiogenesis and molecular pathology. Programs encompass investigators, organized within a specific field of research, who are working together to solve a complex scientific problem. AIDS Vaccine Program – Larry Arthur, Ph.D Computational Applications Program – Stan Burt, Ph.D HIV Drug Resistance Program – John Coffin, Ph.D. Molecular Targets Drug Discovery Program Mouse Cancer Genetics Program – Neal Copeland, Ph.D. Radiation Oncology Sciences Program (ROSP) – C. Norman Coleman, M.D.
  • 2 retirees were added for FY08 David Nelson John Weinstein
  • As in the past % allocation is based on the RRS request system. 12.6 milion was distributed via RRS in FY08; 1.2 million was recouped from the site visit process + an additional 1.595 mil was recovered due to the retirements of John Weinstein, David Nelson and Wayne Anderson.
  • Hope to get to 280-290 and maintain a steady state there. That is if closures/retirements in a year, we should be replacing those positions.

Introduction Introduction Presentation Transcript

  • Center for Cancer Research Update Robert H. Wiltrout, Ph.D., Director Lee A. Helman, M.D., SD for Clinical Research December 9, 2008 NCAB
  • CCR Is An Integral Part of NCI National Cancer Institute Intramural Divisions Extramural Divisions Center to Reduce Cancer Health Disparities Division of Cancer Treatment and Diagnosis Office of Centers, Training, and Resources Division of Cancer Control and Population Sciences Division of Cancer Epidemiology and Genetics Division of Cancer Biology Division of Cancer Prevention
  • CCR Vision Integrate basic, translational, and clinical research to make cancer preventable, curable, or chronically manageable.
  • CCR Mission: Focused On The Patient To inform and empower the entire cancer research community by making breakthrough discoveries in basic and clinical cancer research and by developing them into novel therapeutic interventions for adults and children afflicted with cancer or infected with HIV.
  • CCR Seeks to Achieve Its Mission By:
    • Performing rigorous basic scientific research to discover fundamental mechanisms of biology and cancer
    • Translating these advances rapidly from the laboratory to the clinic
    • Developing innovative technologies that enable more accurate detection, diagnoses, and treatments
    • Pioneering novel interventions for underserved patient populations
    • Sharing expertise, scientific data and technologies to broaden the impact of our work and enhance the overall productivity of the cancer research community
    • Providing a unique environment to cultivate and train future physician-scientists and biomedical researchers
  • CCR ScientificPresenations to the 148 th Meeting of the NCAB
    • Dr. Natasha Caplen - Defining the Cancer Genome using RNAi Analysis and Screening
    • Dr. Stephan Ambs - Application of Genomic Profiling to Identify Factors that contribute to Cancer Health Disparities
    • Dr. Terry Van Dyke - Cancer Models: From Insight to Improved Care
    • Dr. Marston Linehan – The Genetic Basis of Kidney Cancer: Opportunity for Targeted Approaches to Therapy
  • Center for Cancer Research Update – Closed Session Robert H. Wiltrout, Ph.D. Director December 9, 2008 NCAB
  • Distinctive Qualities of CCR
    • Critical mass of basic and clinical scientists solving complex scientific problems
    • Can quickly redeploy resources to address:
      • (a) NCI mission goals-reduce the burden of cancer
      • (b) Urgent public need-response to AIDS epidemic
      • (c) New opportunities-decoding of the human genome
    • Access to NIH Clinical Center
  • Center for Cancer Research: Organization Cellular Oncology Populations Genetics Cell & Cancer Biology Immune Cell Biology Resistance Mechanisms Macromolecular Crystallography Molecular Pharmacology Cancer & Inflammation Cancer Biology and Genetics Cell & Developmental Signaling Cancer Prevention Nanobiology Genomic Diversity Basic Research Cell Biology Molecular Biology Molecular Pharmacology Structural Biophysics Medicinal Chemistry Protein Dynamics & Signaling Molecular Targets Discovery Experimental Immunology Molecular Cell Biology Comparative Carcinogenesis Cell Regulation & Carcinogenesis Molecular Immunoregulation Experimental Carcinogenesis Cancer & Development Biology Human Carcinogenesis Mouse Cancer Genetics Retroviral Replication HIV Drug Resistance Mammary Biology & Tumorigenesis Receptor Biology and Gene Expression HIV Drug Resistance Cellular Carcinogen & Tumor Prom Gene Regulation & Chromosome Biology Cellular & Molecular Biology Biochemistry & Molecular Biology Center for Cancer Research Clinical Branches Basic Laboratories
  • Center for Cancer Research: Organization Dermatology Genetics Medical Oncology Neuro-Oncology Urologic Oncology Pediatric Oncology Experimental Transplant. Immunol. Surgery Experimental Immunology Radiation Oncology Tumor Immunol. & Biology Radiation Biology HIV & AIDS Malignancy Pathology Metabolism Molecular Imaging Biostatistics & Data Mgmt Vaccine Center for Cancer Research Clinical Branches Basic Laboratories
  • CCR Labs and Branches Are Woven Together Around Strategic Priorities
    • Understand the Cancer Process from Initiation to Metastasis
    • Interrogate the Molecular Genetics of Cancer
    • Improve Cancer Prevention, Early Detection, and Diagnostic Approaches
    • Develop and Validate Novel Molecularly Targeted Interventions
    • Harness the Immune System to Combat Cancer
    • Discover and Develop Approaches to Combat HIV/AIDS and AIDS-associated Malignancies
  • Centers of Excellence serve as Focal Points for Bench to Bedside Translation
    • Centers of Excellence serve to support the IRPs dedication to long-term, high-risk, innovative basic, clinical, and epidemiologic research
      • Immunology - Robert Wiltrout, Head
      • Chromosome Biology – Gordon Hager, Head
      • HIV/AIDS and Cancer Virology - Stuart LeGrice, Head
      • Molecular Oncology - Giuseppe Giaccone, Pat Steeg, Head
      • Integrative Biology , Snorri Thorgeirsson, Head
      • Program/Initiative
      • Cancer and Inflammation – Giorgio Trinchieri, Head
  • Strategies for Programmatic Integration Translational Infrastructure Is Collaborative
  • Research Emphasis Today
  • Commercial Successes in Fighting Cancer and HIV Vaccines and Therapeutics 2-F-AraA  - Fludara (April 18, 1991) Berlex Videx  (October 9, 1991) Berlex Lab Hivid (June 19, 1992) BMS Paclitaxel (Dec. 29, 1992) BMS Trimetrexate – Neu Trexin (Dec. 17, 1993) Zenapax (Dec. 10, 1997) Hoffman La Roche Vitravene (Aug. 26, 1998) Isis Pharma Kepivance (Dec. 15, 2004) Amgen Zevalin (Feb. 19, 2002)  IDEC Pharma Gardasil (June 8, 2006) Merck Prezista (June 23, 2006) Tibotec Pharma Diagnostics Serological Detection of Antibodies to HIV-1 (March 1, 1985) Serologic Detection of Antibodies to HTLV-1 (Nov. 29, 1988) DNA Probe for Breast Cancer Diagnosis (Dec. 11, 1998) Multi-replica Blotting Kit for Proteins Instrumentation/Devices Laser Capture Microdissection
    • Jairaj Acharya, MBBS, Ph.D.
    • Laboratory of Cell and
    • Developmental Signaling
    Newly Tenured Phospholipid and sphingolipid signaling in Drosophila
    • Javed Khan, M.D.
    • Pediatric Oncology Branch
    Newly Tenured Applying high throughput genomics and proteomics to characterize high risk pediatric malignancies, focusing on neuroblastoma.
  • 0 20 40 60 80 % of Investigators FY04 N=56 Expansions Continuations Reductions Closures Re-reviews SV & BSC Recommendations N= 10 42 37 5 9 10 58 21 FY05 N=89 FY06 N=76 9 54 13 4 38 16 FY07 N=58 Retirements 12 FY08 N=56
  • FY08 Reallocations of Recovered Funds Basic 45% Translational 27% Clinical 24% Meetings, Retreats 5% 2.8 Million
  • Number of CCR PIs: 2000-2009 * projected Projected 12 additional PIs in FY09 Slide 19
  • Rebuilding the Principal Investigator Community – FY2008
    • Senior Leadership
    • Crystal Mackall, Chief, POB
    • J. Carl Oberholtzer, Chief, LP
    • Kevin Camphausen, Chief, ROB
    • R. Andrew Byrd, Acting Director,
    • Molecular Discovery Program
    • Robert Yarchoan, Director for the
    • NCI Office of HIV and AIDS
    • Malignancies
    • L. Michelle Bennett, Deputy Director
    • CCR
    • Newly Hired Tenure Tracks
    • Itzhak Avital, SB
    • Peter Kalab, LCMB
    • Udai Kammula, SB
    • Yamini Dalal, LRBGE
    • Yinling Hu, LEI
    • Jing Huang, LCBG
    • Jung-Hyun Park, EIB
    • Li Yang, LCBG
    • Joseph Ziegelbauer, HAMB
    • Ola Landgren, MOB
    • Mitchell Ho, LMB
    • Brian Lewis, MB
    • Chris Buck, LOC
    • Deb Citrin, ROB
    • King Kwong, SB
  • Open PI Positions (Nov 2008)
    • Mouse Cancer Genetics Program: 2 Tenure Track or Tenured Positions
    • Laboratory of Human Carcinogenesis: Tenure Track
    • Metabolism Branch: 2 Tenure Track positions
    • Medical Oncology Branch:   Tenure Track in breast cancer
    • Laboratory of Biochemistry and Molecular Biology: Tenure Track
    • Laboratory of Molecular Biology: Tenure Track
    • Chronic Inflammation & Cancer: Tenure Track
    • Neuro Oncology Branch: Tenure Track
  • Major Searches (Nov 2008)
    • Stem Cell Program
    • - 29 applications received
    • - 15 top candidates reviewed by
    • Search Committee
    • - 6 top candidates interviewed
    • Chemical Biology Laboratory
    • Ad has been posted
    • Overwhelmingly positive response from 24 well-qualified applicants, interviews are scheduled with 8 top candidates
  • Center for Cancer Research Update – Closed Session Robert H. Wiltrout, Ph.D. Director December 9, 2008 NCAB
  • The NCI Intramural Clinical Research Program
    • The NCI intramural clinical program is not a large volume, full-service cancer center
    • The NCI intramural clinical program is the largest cancer-focused clinical research center (CRC) in the world, capable of performing patient-intensive clinical research focused on developing new approaches for prevention, diagnosis, and treatment of cancer.
    • The NCI intramural clinical program is an important component of the nation’s overall cancer program